Insights
Search Results
Client Highlights
3.21.24
Wilson Sonsini Advises LENZ Therapeutics on Completed Merger with Graphite Bio
On March 21, 2024, LENZ Therapeutics, Inc., a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye drop that has been shown to improve near vision in people with presbyopia, announced the completion of its previously announced merger with Graphite Bio, Inc. The new combined company will operate under the name LENZ Therapeutics, Inc. and will commence trading on Nasdaq under the ticker symbol “LENZ” on March 22, 2024. Wilson Sonsini Goodrich & Rosati advised LENZ Therapeutics on the transaction.
Client Highlights
11.15.23
Wilson Sonsini Represents LENZ Therapeutics in Merger with Graphite Bio
On November 15, 2023, LENZ Therapeutics, a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies to improve vision, and Graphite Bio, Inc. announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The lead programs of the combined company will address presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over the age of 45. The combined company is expected to trade on Nasdaq under the ticker symbol “LENZ.” Wilson Sonsini Goodrich & Rosati is representing LENZ Therapeutics in the transaction.
Client Highlights
3.07.23
Wilson Sonsini Advises LENZ Therapeutics on $83.5 Million Series B Financing
On March 7, biopharmaceutical company LENZ Therapeutics announced that it raised $83.5 million in an oversubscribed Series B financing. The financing was led by new investor Sectoral Asset Management alongside Alpha Wave Ventures and Point 72. Existing investors RA Capital Management, Versant Ventures, RTW Investments, and others also participated. Wilson Sonsini Goodrich & Rosati represented LENZ in the transaction.